Understand the source comparison
Immune Peptides Overview: Peptide Class Comparison
Understanding which immune peptide serves which research application requires clarity on mechanism, delivery constraints, and evidence depth. The table below compares the three major classes covered in this immune peptides overview. Thymic peptides, antimicrob
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding which immune peptide serves which research application requires clarity on mechanism, delivery constraints, and evidence depth. The table below compares the three major classes covered in this immune peptides overview. Thymic peptides, antimicrobial peptides, and immunoregulatory peptides. Across mechanism, clinical evidence, bioavailability, and primary research applications.
- Thymic Peptides (Thymosin Alpha-1, Thymalin)
- TLR activation, T-cell maturation, IL-2 receptor upregulation
- Hepatitis B/C combination therapy (36% sustained response vs 19% monotherapy. Journal of Viral Hepatitis RCT)
- Subcutaneous 60–70%; oral near-zero due to gastric degradation
- Immune reconstitution, vaccine response enhancement, chronic viral infections
- Best evidence for adaptive immune restoration; requires weeks for T-cell expansion
- Antimicrobial Peptides (LL-37)
- Membrane pore formation, endotoxin neutralization, neutrophil chemotaxis via FPRL1
- MRSA/P. aeruginosa activity at 2–10 μg/mL (Nature Medicine); wound healing acceleration in diabetic models
- Topical application effective; systemic half-life <30 min due to protease degradation
- Wound healing, mucosal defense, antibiotic-resistant infection models
- Innate mechanism prevents resistance; delivery route determines outcome
- Immunoregulatory Peptides (KPV, VIP)
- NF-κB suppression, VPAC receptor-mediated Treg expansion, cytokine profile shift to IL-10/TGF-β
- Colitis models: 54% disease activity reduction (J Pharmacol Exp Ther); EAE prevention via Treg expansion (PNAS)
- KPV oral 5–8% (advantage for mucosal delivery); VIP systemic requires parenteral route
- Inflammatory bowel models, autoimmune neuroinflammation, chronic inflammation suppression
- Selective pathway inhibition without broad immunosuppression; tissue-specific effects
- The bottom line from this immune peptides overview: thymic peptides restore adaptive immunity over weeks, antimicrobial peptides provide rapid innate defense limited by stability, and immunoregulatory peptides suppress inflammation selectively in specific tissue contexts. Mechanism determines application. No single class solves all immune dysfunction.